Patient, donor, disease, and transplant characteristics according to the development of post-transplantation pp65-antigenemia
| . | All patients . | Patients with pp65-antigenemia . | Patients without pp65-antigenemia . | P . |
|---|---|---|---|---|
| Patients, no. (%) | 266 (100) | 77 (29) | 189 (71) | — |
| Male patients, no. (%) | 137 (52) | 38 (49) | 99 (52) | NS |
| Median patient age, y (range) | 47 (18-73) | 47 (19-68) | 46 (18-73) | NS |
| Patient age, y, no. (%) | ||||
| Younger than 20 | 8 (3) | 1 (1) | 7 (4) | |
| 20-40 | 90 (34) | 28 (36) | 62 (33) | NS |
| Older than 40 | 168 (63) | 48 (62) | 120 (63) | |
| Median donor age, y (range) | 40 (10-70) | 40 (12-70) | 40 (10-70) | NS |
| Donor type, no. (%) | ||||
| Identical sibling | 118 (44) | 29 (38) | 89 (47) | NS |
| Matched unrelated | 148 (56) | 48 (62) | 100 (53) | |
| Donor/patient sex, no. (%) | ||||
| Female/male | 28 (11) | 8 (10) | 20 (11) | NS |
| Other combinations | 238 (89) | 69 (90) | 169 (89) | |
| Donor/patient HCMV serology, no. (%) | ||||
| Negative/negative | 99 (37) | 4 (5) | 95 (50) | < .0002 |
| Positive/positive | 125 (47) | 57 (74) | 68 (36) | |
| Positive/negative | 8 (3) | 2 (3) | 6 (3) | |
| Negative/positive | 34 (13) | 14 (18) | 20 (11) | |
| Negative/negative | 99 (37) | 4 (5) | 95 (50) | < .0001 |
| Other combinations | 167 (63) | 73 (95) | 94 (50) | |
| Disease etiology, no. (%) | ||||
| De novo | 222 (83) | 64 (83) | 158 (84) | NS |
| Secondary | 26 (19) | 11 (14) | 15 (8) | |
| Therapy-related | 18 (7) | 2 (3) | 16 (8) | |
| Disease stage, no. (%) | ||||
| First remission | 123 (46) | 34 (44) | 89 (47) | |
| Second remission | 61 (23) | 18 (23) | 43 (23) | NS |
| Other stages | 82 (31) | 25 (31) | 57 (30) | |
| Disease genetic group, no. (%)* | ||||
| Favorable | 25 (9) | 4 (5) | 21 (11) | NS |
| Intermediate | 147 (55) | 47 (61) | 100 (53) | |
| Adverse | 94 (35) | 26 (34) | 68 (36) | |
| Stem cell source, no. (%) | ||||
| Bone marrow | 45 (17) | 10 (13) | 35 (19) | NS |
| Peripheral blood | 221 (83) | 67 (87) | 154 (81) | |
| Preparative regimen, no. (%) | ||||
| TBI + chemotherapy | 164 (62) | 40 (52) | 124 (66) | NS |
| Chemotherapy alone | 102 (38) | 37 (48) | 65 (34) | |
| Immune prophylaxis, no. (%) | ||||
| sMTX + CsA | 259 (97) | 74 (96) | 185 (98) | NS |
| MMF + CsA | 7 (3) | 3 (4) | 4 (2) |
| . | All patients . | Patients with pp65-antigenemia . | Patients without pp65-antigenemia . | P . |
|---|---|---|---|---|
| Patients, no. (%) | 266 (100) | 77 (29) | 189 (71) | — |
| Male patients, no. (%) | 137 (52) | 38 (49) | 99 (52) | NS |
| Median patient age, y (range) | 47 (18-73) | 47 (19-68) | 46 (18-73) | NS |
| Patient age, y, no. (%) | ||||
| Younger than 20 | 8 (3) | 1 (1) | 7 (4) | |
| 20-40 | 90 (34) | 28 (36) | 62 (33) | NS |
| Older than 40 | 168 (63) | 48 (62) | 120 (63) | |
| Median donor age, y (range) | 40 (10-70) | 40 (12-70) | 40 (10-70) | NS |
| Donor type, no. (%) | ||||
| Identical sibling | 118 (44) | 29 (38) | 89 (47) | NS |
| Matched unrelated | 148 (56) | 48 (62) | 100 (53) | |
| Donor/patient sex, no. (%) | ||||
| Female/male | 28 (11) | 8 (10) | 20 (11) | NS |
| Other combinations | 238 (89) | 69 (90) | 169 (89) | |
| Donor/patient HCMV serology, no. (%) | ||||
| Negative/negative | 99 (37) | 4 (5) | 95 (50) | < .0002 |
| Positive/positive | 125 (47) | 57 (74) | 68 (36) | |
| Positive/negative | 8 (3) | 2 (3) | 6 (3) | |
| Negative/positive | 34 (13) | 14 (18) | 20 (11) | |
| Negative/negative | 99 (37) | 4 (5) | 95 (50) | < .0001 |
| Other combinations | 167 (63) | 73 (95) | 94 (50) | |
| Disease etiology, no. (%) | ||||
| De novo | 222 (83) | 64 (83) | 158 (84) | NS |
| Secondary | 26 (19) | 11 (14) | 15 (8) | |
| Therapy-related | 18 (7) | 2 (3) | 16 (8) | |
| Disease stage, no. (%) | ||||
| First remission | 123 (46) | 34 (44) | 89 (47) | |
| Second remission | 61 (23) | 18 (23) | 43 (23) | NS |
| Other stages | 82 (31) | 25 (31) | 57 (30) | |
| Disease genetic group, no. (%)* | ||||
| Favorable | 25 (9) | 4 (5) | 21 (11) | NS |
| Intermediate | 147 (55) | 47 (61) | 100 (53) | |
| Adverse | 94 (35) | 26 (34) | 68 (36) | |
| Stem cell source, no. (%) | ||||
| Bone marrow | 45 (17) | 10 (13) | 35 (19) | NS |
| Peripheral blood | 221 (83) | 67 (87) | 154 (81) | |
| Preparative regimen, no. (%) | ||||
| TBI + chemotherapy | 164 (62) | 40 (52) | 124 (66) | NS |
| Chemotherapy alone | 102 (38) | 37 (48) | 65 (34) | |
| Immune prophylaxis, no. (%) | ||||
| sMTX + CsA | 259 (97) | 74 (96) | 185 (98) | NS |
| MMF + CsA | 7 (3) | 3 (4) | 4 (2) |
TBI indicates total body irradiation; sMTX, short-course methotrexate; CsA, cyclosporine A; MMF, mycophenolate mofetil; —, not applicable; and NS, not significant (P ≥ .01).
Favorable indicates t(8;12) or RUNX1-RUNX1T1; inv(16)(p13q22); t(16;16)(p13q22) or CBFB-MYH11; t(15;17); normal karyotype and mutated NPM1 without FLT3-ITD or mutated CEBPA.10 Intermediate indicates cytogenetic or molecular genetic abnormalities not classified as favorable or adverse.10 Adverse indicates inv(3)(q21q26.2) or t(3;3)(q21;q26.2) or RPN1-EVI1; t(6;9)(p23;q34) or DEK-NUP214; t(v;11)(v;q23) or MLL rearranged; −5 or del(5q); −7; abnl(17p); complex karyotype.10